Lucid Diagnostics Inc (LUCD) Stock Price, Quote & News

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths t...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.luciddx.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

alan99 Apr. 14 at 2:02 PM

$LUCD we got some volume!

0 · Reply

minnesotafarmcountry Apr. 14 at 2:02 PM

$LUCD Another huge block 💥

0 · Reply

tds_ Apr. 14 at 1:57 PM

$LUCD

0 · Reply

KYLE0829 Apr. 14 at 1:55 PM

$LUCD wowza, has my attention

0 · Reply

Lets_Go_Brndn Apr. 14 at 1:42 PM

$LUCD 👇👇👇 https://x.com/crypto_biotech/status/2044048174344441939?s=46

0 · Reply

minnesotafarmcountry Apr. 13 at 11:25 PM

$LUCD And, there’s this NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT. The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website

1 · Reply

RunnerSignals Apr. 13 at 8:36 PM

$TVTX $LUCD $CCCC flow confirms early momentum shift above key mas while consensus still treats this as noise

0 · Reply

minnesotafarmcountry Apr. 13 at 8:09 PM

$LUCD No penny flippers eod today? 🤷‍♀️

0 · Reply

lidopete Apr. 13 at 8:08 PM

$LUCD target raised to $9 from $8.25 at Ascendiant Apr 9, 6:41 AM Ascendiant analyst Edward Woo raised the firm's price target on Lucid Diagnostics to $9 from $8.25 and keeps a Buy rating on the shares post the Q4 report. The firm says the company's "high growth" and Medicare coverage starting should drive the stock "much higher."

2 · Reply

Lets_Go_Brndn Apr. 13 at 8:03 PM

$LUCD Great day folks! I added earlier. Opportunity cost? This is it. Also- I am not a blind bull like other folks are about BioPharm positions they own. This is the second company I own (Ardekyx is the other) that I do not like management, but own it and think they will do well despite management.

0 · Reply

Market Cap	203.49M
Revenue (ttm)	4.71M
Net Income (ttm)	-58.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,231.63%
Debt to Equity Ratio	2.19

Volume	963,700
Avg Vol	707,262
Day's Range	N/A - N/A
Shares Out	176.95M
Stochastic %K	94%
Beta	1.24
Analysts	Strong Sell
Price Target	$4.10